>>Signaling Pathways>> Stem Cell>> YAP>>GA-017

GA-017

Catalog No.GC65116

GA-017은 IC50 값이 각각 4.10 및 3.92nM인 강력하고 선택적인 LATS1 및 LATS2(대형 종양 억제 키나제 1/2) 억제제입니다. GA-017은 세포 증식의 활성제입니다. GA-017은 YAP/TAZ 활성화 및 핵 전위를 촉진합니다. GA-017은 3D 배양 조건에서 세포 성장을 촉진합니다. GA-017은 마우스 장 오르가노이드의 생체 외 형성을 향상시킵니다.

Products are for research use only. Not for human use. We do not sell to patients.

GA-017 Chemical Structure

Cas No.: 2351906-74-4

Size 가격 재고 수량
5mg
US$198.00
재고 있음
10mg
US$306.00
재고 있음
25mg
US$558.00
재고 있음
50mg
US$855.00
재고 있음
100mg
US$1,350.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Chemical Properties Product Documents

GA-017 is a potent and selective LATS1 and LATS2 (large tumor suppressor kinase 1/2) inhibitor, with IC50 values of 4.10 and 3.92 nM, respectively. GA-017 is an activator of cell proliferation. GA-017 promotes YAP/TAZ activation and nuclear translocation. GA-017 promotes cell growth under 3D culture conditions. GA-017 enhances the ex vivo formation of mouse intestinal organoids[1].

GA-017 suppresses the cell death of HUVECs and promotes their cell growth[1].GA-017 facilitates SKOV3 cell growth, with an EC50 of 3.51 ± 0.26 μM[1].GA-017 competitively inhibited LATS1 and 2 against ATP, with Ki (inhibition constant) values of 0.58 ± 0.11 and 0.25 ± 0.03 nM, respectively[1].

[1]. Aihara A, et al. Small molecule LATS kinase inhibitors block the Hippo signaling pathway and promote cell growth under 3D culture conditions. J Biol Chem. 2022 Apr;298(4):101779.

리뷰

Review for GA-017

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for GA-017

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.